Abstract
Gout is a common condition which is mainly treated with the hypo‐uricemic agent, allopurinol. Although allopurinol is generally a well‐tolerated drug, there is a small risk of developing potentially fatal complications, such as allopurinol hypersensitivity syndrome. Recent advances in pharmacogenomics have made possible the identification of genes which confer susceptibility to specific drugs. A recent multi‐national case‐control study has reported allopurinol as the most common drug associated with Stevens‐Johnson syndrome and toxic epidermal necrolysis. Several studies have established a strong association between the human leukocyte antigen (HLA)‐B*5801 gene and development of Stevens‐Johnson syndrome and toxic epidermal necrolysis. The allele frequency of HLA‐B*5801 is highest in the South East Asian population.Since other hypo‐uricemic agents are available, patients may wish to have HLA‐B*5801 testing before being started on allopurinol. As the test for HLA‐B*5801 is expensive, time‐consuming and only available in selected laboratories, there is a need to evaluate the utility and cost‐effectiveness of this test in our region.

This publication has 21 references indexed in Scilit: